Novartis sees off ICC claim over pain relief drug
A US subsidiary of Swiss pharmaceuticals group Novartis has defeated a US$82 million ICC claim brought by a former Japanese partner over its decision to discontinue development of a pain relief drug.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10